Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. (Q54572400)

1 June 2018

title

Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. (English)

1 reference

1 June 2018

main subject

dasatinib monohydrate

1 reference

1 reference

4

Yoshinori Ito

1 reference

1 June 2018

Shunji Takahashi

1

object named as

Shunji Takahashi

1 reference

1 June 2018

Kiyohiko Hatake

8

object named as

Kiyohiko Hatake

1 reference

1 June 2018

author name string

Masaki Miyazaki

2

1 reference

1 June 2018

Isamu Okamoto

3

1 reference

1 June 2018

Kyoji Ueda

5

1 reference

1 June 2018

Taku Seriu

6

1 reference

1 June 2018

Kazuhiko Nakagawa

7

1 reference

1 June 2018

publication date

1 September 2011

1 reference

1 June 2018

published in

Cancer Science

1 reference

1 June 2018

volume

102

1 reference

1 June 2018

issue

11

1 reference

1 June 2018

page(s)

2058-2064

1 reference

1 June 2018

Src family kinases in tumor progression and metastasis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Src family kinases, key regulators of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Src kinase activity is essential for osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

pp60c-src activation in human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Dasatinib induces a response in malignant thymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Thymic tumorigenesis induced by overexpression of p56lck

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02041.X

10.1111/J.1349-7006.2011.02041.X

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018